[18F]FAPI-74 (FAPI-PRO)

About Sofie

SOFIE is an integrated radiopharmaceutical company operating across the theranostics value chain, from proprietary R&D to commercial manufacturing and distribution. The company's strategy is built on three pillars: advancing its proprietary pipeline of Fibroblast Activation Protein Inhibitor (FAPI)-based PET imaging agents, providing contract development and manufacturing (CDMO) services through its Theranostics Center of Excellence, and distributing radiopharmaceuticals via a network of 14 radiopharmacies. With its lead candidate, [18F]FAPI-74, in Phase 3 trials for pancreatic and gastroesophageal cancers, SOFIE is positioning itself as a key player in the expanding field of precision oncology and targeted radiotherapy. The company combines service revenue with high-value intellectual property development.

Therapeutic Areas

Other Pancreatic Ductal Adenocarcinoma Drugs